{"id":2241,"date":"2022-01-20T00:00:00","date_gmt":"2022-01-20T00:00:00","guid":{"rendered":"http:\/\/centogene.vl22350.dinaserver.com\/2241"},"modified":"2022-01-20T00:00:00","modified_gmt":"2022-01-20T00:00:00","slug":"centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery","status":"publish","type":"post","link":"https:\/\/www.centogene.com\/pl\/centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery\/","title":{"rendered":"CENTOGENE \u0142\u0105czy si\u0142y z Insilico Medicine w celu odkrywania cel\u00f3w w chorobie Niemanna-Picka typu C (NPC), stosuj\u0105c sztuczn\u0105 inteligencj\u0119 (AI) w celu przyspieszenia rozwoju lek\u00f3w sierocych"},"content":{"rendered":"<ul>\n<li>CENTOGENE and Insilico Medicine will work together to identify, rank, and annotate proteins to identify novel therapeutic targets for NPC using AI<\/li>\n<li>NPC is a rare genetic disease occurring in approximately 1 in 120,000 live births, with many cases going mis- or undiagnosed<\/li>\n<li>There are currently no FDA-approved treatments for NPC<\/li>\n<\/ul>\n<p>CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, January 20, 2022 (GLOBE NEWSWIRE \u2013 Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand and treat rare diseases, and Insilico Medicine, an end-to-end Artificial Intelligence (AI) -driven drug discovery company, today announced a research and development collaboration to accelerate the discovery of novel therapeutic targets for Niemann-Pick disease type C. The duration of the research collaboration will initially last 20 weeks.<\/p>\n<p>As the framework for the collaboration, CENTOGENE will leverage its Bio\/Databank with multiomic patient data and NPC cell lines (for transcriptomic data and validation of identified candidates), through the use of Insilico\u2019s comprehensive novel target discovery AI platform for the identification of differential metabolites, pathways, and genetic modifiers. Both Companies will analyze identified targets before pursuing validation in CENTOGENE\u2019s cellular models, and CENTOGENE will retain exclusive rights to any intellectual property generated by the research.<\/p>\n<p>\u201cI am thrilled by the collaboration between CENTOGENE and Insilico. With the power of AI, we will accelerate the analysis and knowledge discovery of multiomic data from patients affected with NPC,\u201d said Patrice Den\u00e8fle, Chief Scientific Officer at CENTOGENE. \u201cUsing relevant human cellular models, we hope to crack the code and validate meaningful and valuable insights on a disease for which no cure has been found over the past decades using traditional pharma approaches.\u201d<\/p>\n<p>\u201cCENTOGENE\u2019s rare disease-centric Bio\/Databank is unique in the richness of the data it holds. By leveraging Insilico\u2019s powerful proprietary AI platform, PandaOmics, with the multiomic research data from CENTOGENE, I hope our collaboration will result in the discovery of a therapeutic target for NPC,\u201d said Alex Zhavoronkov, Ph.D., Founder and CEO of Insilico Medicine. \u201cUltimately we want to improve the quality of life for those affected by the disease and bring tangible hope to thousands of NPC patients around the world.\u201d<\/p>\n<p>If the research demonstrates translational robustness, a further stage of drug development would become accessible \u2013 identifying molecules that act on the identified targets. AI-based methods are expected to accelerate this process \u2013 ultimately turning years into months for both the target-to-hit and hit-to-lead phases.<\/p>\n<p>\u201cWe are excited to be working together with Insilico as we seek to identify novel therapeutic targets for NPC,\u201d added Carsten Ullrich, Ph.D., Senior Director of Artificial Intelligence at CENTOGENE. \u201cCombining both CENTOGENE\u2019s expertise in multiomics and unique global insights from the world\u2019s largest NPC cohort with Insilico\u2019s next-generation AI platform has the potential to enable an accelerated cure for this rare and often rapidly progressing disease.\u201d<\/p>\n<p>To learn more about CENTOGENE\u2019s AI Program, visit: <a href=\"https:\/\/www.centogene.com\/pl\/science\/artificial-intelligence-initiative.html\/\" target=\"_blank\" title=\"More about CENTOGENE`s AI Program\">https:\/\/www.centogene.com\/science\/artificial-intelligence-initiative.html<\/a><\/p>\n<p>This collaboration represents another significant step forward for CENTOGENE\u2019s mission to enable the cure of 100 rare diseases within the next 10 years. To learn more, visit: <a href=\"https:\/\/www.centogene.com\/pl\/virtual-investor-event\/\" target=\"_blank\" title=\"Dowiedz si\u0119 wi\u0119cej\">https:\/\/www.centogene.com\/virtual-investor-event<\/a><\/p>\n<h4>About Niemann-Pick Disease Type C (NPC)<\/h4>\n<p>Niemann-Pick disease type C (NPC) is a genetic lipid storage disease caused by mutations in the NPC1 and NPC2 genes that lead to a heterogeneous spectrum of symptoms. This may include ataxia, dystonia, vertical supranuclear gaze palsy, severe liver disease, and interstitial lung disease, among others.<\/p>\n<p>Onset may occur at varying ages, from neonatal to adulthood. Life expectancy is reduced, and the estimated incidence is approximately 1 in 120,000 births. It is important to note that many cases go mis- or undiagnosed \u2013 creating difficulty around determining the true frequency of NPC.<\/p>\n<h4>About Insilico Medicine<\/h4>\n<p>Insilico Medicine, an end-to-end artificial intelligence-driven drug discovery company, is developing artificial intelligence platforms. These platforms use deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, infectious diseases, autoimmune diseases, and aging-related diseases. For more information, please visit <a href=\"https:\/\/www.insilico.com\" target=\"_blank\" title=\"Visit Insilico\">www.insilico.com<\/a>.<\/p>\n<h4>O firmie CENTOGENE<\/h4>\n<p>CENTOGENE zajmuje si\u0119 diagnostyk\u0105 i badaniami nad chorobami rzadkimi, przekszta\u0142caj\u0105c rzeczywiste dane kliniczne, genetyczne i multiomiczne w celu diagnozowania, zrozumienia i leczenia chor\u00f3b rzadkich. Naszym celem jest racjonalizacja decyzji terapeutycznych i przyspieszenie rozwoju nowych lek\u00f3w sierocych poprzez wykorzystanie naszej rozleg\u0142ej wiedzy i danych na temat chor\u00f3b rzadkich. CENTOGENE opracowa\u0142o globaln\u0105, autorsk\u0105 platform\u0119 bada\u0144 nad chorobami rzadkimi, opart\u0105 na naszym repozytorium danych dotycz\u0105cych ponad 600 000 pacjent\u00f3w z ponad 120 kraj\u00f3w.<\/p>\n<p>Platforma firmy obejmuje dane epidemiologiczne, fenotypowe i genetyczne, kt\u00f3re odzwierciedlaj\u0105 globaln\u0105 populacj\u0119, a tak\u017ce biobank pr\u00f3bek krwi pacjent\u00f3w i kultur kom\u00f3rkowych. CENTOGENE uwa\u017ca, \u017ce jest to jedyna platforma skoncentrowana na kompleksowej analizie danych wielopoziomowych w celu lepszego zrozumienia rzadkich chor\u00f3b dziedzicznych. Umo\u017cliwia ona lepsz\u0105 identyfikacj\u0119 i stratyfikacj\u0119 pacjent\u00f3w oraz ich chor\u00f3b podstawowych, co umo\u017cliwia i przyspiesza odkrywanie, rozw\u00f3j i dost\u0119p do lek\u00f3w sierocych. Na dzie\u0144 31 grudnia 2020 r. firma wsp\u00f3\u0142pracowa\u0142a z ponad 30 partnerami farmaceutycznymi.<\/p>\n<p>Obserwuj nas na <a href=\"https:\/\/de.linkedin.com\/company\/centogene\" target=\"_blank\" title=\"Link To LinkedIn\">LinkedIn<\/a><\/p>\n<h4>O\u015bwiadczenia prognostyczne<\/h4>\n<p>Niniejsza informacja prasowa zawiera \u201co\u015bwiadczenia prognostyczne\u201d w rozumieniu federalnych przepis\u00f3w dotycz\u0105cych papier\u00f3w warto\u015bciowych w Stanach Zjednoczonych. Zawarte w niej o\u015bwiadczenia, kt\u00f3re nie maj\u0105 jednoznacznie historycznego charakteru, maj\u0105 charakter prognostyczny, a s\u0142owa \u201cprzewidywa\u0107\u201d, \u201cwierzy\u0107\u201d, \u201ckontynuowa\u0107\u201d, \u201coczekiwa\u0107\u201d, \u201cszacowa\u0107\u201d, \u201czamierza\u0107\u201d, \u201cprognozowa\u0107\u201d oraz podobne wyra\u017cenia i czasowniki w czasie przysz\u0142ym lub warunkowym, takie jak \u201cb\u0119dzie\u201d, \u201cby\u0142by\u201d, \u201cpowinien\u201d, \u201cm\u00f3g\u0142by\u201d, \u201cmo\u017ce\u201d, \u201cmo\u017ce\u201d i \u201cmo\u017ce\u201d, maj\u0105 na celu identyfikacj\u0119 o\u015bwiadcze\u0144 prognostycznych. Takie o\u015bwiadczenia prognostyczne wi\u0105\u017c\u0105 si\u0119 ze znanymi i nieznanymi ryzykami, niepewno\u015bciami i innymi istotnymi czynnikami, kt\u00f3re mog\u0105 spowodowa\u0107, \u017ce rzeczywiste wyniki, efektywno\u015b\u0107 lub osi\u0105gni\u0119cia CENTOGENE b\u0119d\u0105 istotnie r\u00f3\u017cni\u0107 si\u0119 od jakichkolwiek przysz\u0142ych wynik\u00f3w, efektywno\u015bci lub osi\u0105gni\u0119\u0107 wyra\u017conych lub dorozumianych w o\u015bwiadczeniach prognostycznych. Takie ryzyka i niepewno\u015bci obejmuj\u0105 mi\u0119dzy innymi negatywne warunki gospodarcze na ca\u0142ym \u015bwiecie oraz ci\u0105g\u0142\u0105 niestabilno\u015b\u0107 i zmienno\u015b\u0107 na \u015bwiatowych rynkach finansowych, wp\u0142yw pandemii COVID-19 na nasz\u0105 dzia\u0142alno\u015b\u0107 i wyniki operacyjne, mo\u017cliwe zmiany w obowi\u0105zuj\u0105cych i proponowanych przepisach, regulacjach i politykach rz\u0105dowych, presj\u0119 wynikaj\u0105c\u0105 ze wzrostu konkurencji i konsolidacji w naszej bran\u017cy, koszty i niepewno\u015b\u0107 zwi\u0105zan\u0105 z zatwierdzeniem regulacyjnym, w tym przez Ameryka\u0144sk\u0105 Agencj\u0119 ds. \u017bywno\u015bci i Lek\u00f3w, nasze uzale\u017cnienie od stron trzecich i partner\u00f3w, w tym nasz\u0105 zdolno\u015b\u0107 do zarz\u0105dzania wzrostem i nawi\u0105zywania nowych relacji z klientami, nasz\u0105 zale\u017cno\u015b\u0107 od bran\u017cy chor\u00f3b rzadkich, nasz\u0105 zdolno\u015b\u0107 do zarz\u0105dzania ekspansj\u0105 mi\u0119dzynarodow\u0105, nasz\u0105 zale\u017cno\u015b\u0107 od kluczowego personelu, nasz\u0105 zale\u017cno\u015b\u0107 od ochrony w\u0142asno\u015bci intelektualnej, wahania naszych wynik\u00f3w operacyjnych spowodowane wp\u0142ywem kurs\u00f3w walutowych, nasz\u0105 zdolno\u015b\u0107 do usprawnienia wykorzystania got\u00f3wki, nasze zapotrzebowanie na dodatkowe finansowanie i nasz\u0105 zdolno\u015b\u0107 do kontynuowania dzia\u0142alno\u015bci lub inne czynniki. Aby uzyska\u0107 wi\u0119cej informacji na temat ryzyka i niepewno\u015bci, kt\u00f3re mog\u0105 spowodowa\u0107, \u017ce rzeczywiste wyniki b\u0119d\u0105 si\u0119 r\u00f3\u017cni\u0107 od tych wyra\u017conych w niniejszych o\u015bwiadczeniach prognostycznych, a tak\u017ce ryzyka zwi\u0105zanego z dzia\u0142alno\u015bci\u0105 CENTOGENE og\u00f3lnie, zapoznaj si\u0119 z czynnikami ryzyka CENTOGENE przedstawionymi w formularzu 20-F z\u0142o\u017conym przez CENTOGENE 15 kwietnia 2021 r. w Komisji Papier\u00f3w Warto\u015bciowych i Gie\u0142d (SEC) oraz w p\u00f3\u017aniejszych dokumentach z\u0142o\u017conych w SEC. Wszelkie o\u015bwiadczenia prognostyczne zawarte w niniejszym komunikacie prasowym obowi\u0105zuj\u0105 wy\u0142\u0105cznie na dzie\u0144 jego sporz\u0105dzenia, a CENTOGENE wyra\u017anie zrzeka si\u0119 obowi\u0105zku aktualizacji jakichkolwiek o\u015bwiadcze\u0144 prognostycznych, niezale\u017cnie od tego, czy wynika to z nowych informacji, przysz\u0142ych zdarze\u0144, czy z innych przyczyn.<\/p>\n<h5>Kontakt dla medi\u00f3w: &nbsp;<\/h5>\n<p>CENTOGENE<br \/> Ben Legg<br \/> Komunikacja korporacyjna&nbsp;<br \/> <a href=\"mailto:press@centogene.com\" title=\"Napisz e-mail\">press(at)centogene(dot)com<\/a><\/p>\n<p>Lennart Streibel<br \/> Relacje inwestorskie<br \/> <a href=\"mailto:investor.relations@centogene.com\" title=\"Napisz e-mail\">investor.relations(at)centogene(dot)com<\/a>&nbsp;<\/p>\n<p>Stern IR &nbsp;<br \/> Brendan Payne<br \/> +1 (212) 698 8695<br \/> <a href=\"mailto:brendan.payne@sternir.com\" title=\"Napisz e-mail\">brendan.payne(at)sternir(dot)com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>CENTOGENE and Insilico Medicine will work together to identify, rank, and annotate proteins to identify novel therapeutic targets for NPC [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2241","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development | CENTOGENE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.centogene.com\/pl\/centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery\/\" \/>\n<meta property=\"og:locale\" content=\"pl_PL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development | CENTOGENE\" \/>\n<meta property=\"og:description\" content=\"CENTOGENE and Insilico Medicine will work together to identify, rank, and annotate proteins to identify novel therapeutic targets for NPC [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.centogene.com\/pl\/centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery\/\" \/>\n<meta property=\"og:site_name\" content=\"CENTOGENE\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-20T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"740\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admincg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Napisane przez\" \/>\n\t<meta name=\"twitter:data1\" content=\"admincg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Szacowany czas czytania\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery\\\/\"},\"author\":{\"name\":\"admincg\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\"},\"headline\":\"CENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development\",\"datePublished\":\"2022-01-20T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery\\\/\"},\"wordCount\":1266,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery\\\/\",\"name\":\"CENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development | CENTOGENE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\"},\"datePublished\":\"2022-01-20T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery\\\/#breadcrumb\"},\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.centogene.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"name\":\"CENTOGENE\",\"description\":\"Guiding Precision Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.centogene.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pl-PL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\",\"name\":\"CENTOGENE\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pl-PL\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"contentUrl\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"width\":246,\"height\":246,\"caption\":\"CENTOGENE\"},\"image\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/centogene\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClZxtN_laC1_ZtCdxkasdPQ\",\"https:\\\/\\\/www.instagram.com\\\/_centogene_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\",\"name\":\"admincg\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/pl\\\/author\\\/admincg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development | CENTOGENE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.centogene.com\/pl\/centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery\/","og_locale":"pl_PL","og_type":"article","og_title":"CENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development | CENTOGENE","og_description":"CENTOGENE and Insilico Medicine will work together to identify, rank, and annotate proteins to identify novel therapeutic targets for NPC [&hellip;]","og_url":"https:\/\/www.centogene.com\/pl\/centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery\/","og_site_name":"CENTOGENE","article_published_time":"2022-01-20T00:00:00+00:00","og_image":[{"width":740,"height":416,"url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp","type":"image\/webp"}],"author":"admincg","twitter_card":"summary_large_image","twitter_misc":{"Napisane przez":"admincg","Szacowany czas czytania":"6 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.centogene.com\/centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery\/#article","isPartOf":{"@id":"https:\/\/www.centogene.com\/centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery\/"},"author":{"name":"admincg","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b"},"headline":"CENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development","datePublished":"2022-01-20T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.centogene.com\/centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery\/"},"wordCount":1266,"commentCount":0,"publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"pl-PL","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.centogene.com\/centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.centogene.com\/centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery\/","url":"https:\/\/www.centogene.com\/centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery\/","name":"CENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development | CENTOGENE","isPartOf":{"@id":"https:\/\/www.centogene.com\/#website"},"datePublished":"2022-01-20T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.centogene.com\/centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery\/#breadcrumb"},"inLanguage":"pl-PL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.centogene.com\/centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.centogene.com\/centogene-joins-forces-with-insilico-medicine-for-niemann-pick-disease-type-c-npc-target-discovery\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.centogene.com\/"},{"@type":"ListItem","position":2,"name":"CENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development"}]},{"@type":"WebSite","@id":"https:\/\/www.centogene.com\/#website","url":"https:\/\/www.centogene.com\/","name":"CENTOGENE","description":"Kierowanie medycyn\u0105 precyzyjn\u0105","publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.centogene.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pl-PL"},{"@type":"Organization","@id":"https:\/\/www.centogene.com\/#organization","name":"CENTOGENE","url":"https:\/\/www.centogene.com\/","logo":{"@type":"ImageObject","inLanguage":"pl-PL","@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","contentUrl":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","width":246,"height":246,"caption":"CENTOGENE"},"image":{"@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/centogene","https:\/\/www.youtube.com\/channel\/UClZxtN_laC1_ZtCdxkasdPQ","https:\/\/www.instagram.com\/_centogene_\/"]},{"@type":"Person","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b","name":"admincg","url":"https:\/\/www.centogene.com\/pl\/author\/admincg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2241","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/comments?post=2241"}],"version-history":[{"count":0,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2241\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/media?parent=2241"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/categories?post=2241"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/tags?post=2241"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}